Back to results
US 11,028,445 B2Granted
Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof
AssigneeCelera Corporation
InventorsKit Lau, Alice Wang
Life of this patent
Estimating the term…
Abstract
The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis.
Claims16
A method of treating a human at risk for breast cancer metastasis, the method comprising:
- (a) measuring mRNA expression levels of genes comprising CENPA, PKMYT1, MELK, BUB1, RACGAP1, TK1, UBE2S, DC13, RFC4, PRR11, DIAPH3, and ORC6L in estrogen receptor-positive tumor cells from said human to generate a sum total of said expression levels wherein the mRNA of each of said genes is reverse transcribed and amplified using at least one primer associated with the corresponding gene comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-2, 5-12, and 15-28;
- (b) determining said human is at risk for breast cancer metastasis when said sum total exceeds a predefined cutoff threshold;
- and
- (c) administering a breast cancer therapy to said human.
1 more element
Dependencies are inferred from the claim text.